Print

ANDA Litigation Settlements

Case Name Drug Patent No(s). Publicly Available Terms
Novartis Pharms. Corp. v. Amneal Pharms. LLC, 15-1025 (D. Del.) Exelon® Patch (rivastigmine transdermal system)
6,316,023
6,335,031
N/A.
AstraZeneca AB v. Micro Labs USA, Inc., 15-3376, 15-7921 (D.N.J.) Daliresp® (roflumilast tablets)
5,712,298
8,431,154
8,604,064
8,618,142
8,536,206
N/A
Warner Chilcott (US), LLC v. Zydus Pharms. (USA), Inc., 16-0323 (E.D. Tex.) Delzicol® (mesalamine delayed-release capsules)
6,649,180
Zydus and Cadila may market a generic version of Delzicol in the US starting on March 1, 2020, pending FDA approval, or earlier under certain circumstances.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.